Fate Therapeutics, Inc. (FATE) News
Track canonical SquawkNews coverage tagged to FATE, Fate Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Fate Therapeutics reports Q2 2026 financial results and business updates
Fate Therapeutics (FATE) reports its second quarter 2026 financial results and provides business updates, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:31 PM UTC
L
Fate Therapeutics Reports New Employee Awards
Fate Therapeutics grants new employee inducement awards
EQUITY | Aug 03, 2026, 08:05 PM UTC
H
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE: PXED ) fell sharply in pre-market trading after the
EARNINGS | Jul 15, 2026, 12:02 PM UTC
L
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
() -- (Updates to add the latest stock move in the headline and the first paragraph.) Fate Therapeutics (FATE) shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the compan
REGULATION | Jul 09, 2026, 06:48 PM UTC
L
Fate Therapeutics announces FDA clearance of FT839 IND application
Fate Therapeutics announced that the FDA has cleared its investigational new drug, or IND, application for FT839, the company's next-generation, off-the-shelf CAR T-cell product candidate engineered to co-target CD19 and
EQUITY | Jul 09, 2026, 01:25 PM UTC
L
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISS
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio
EQUITY | Jul 06, 2026, 12:30 PM UTC